The Superintendent of Public Health has issued an updated list of products with the active substance valsartan that may be potentially impacted by the N-nitrosodimethylamine (NDMA) impurity.

 

 

 

It is important to note that treatment should not be stopped until the patient has been prescribed an alternative. The health risk of discontinuing this medicine is higher than any potential risk presented by the impurity. At present there is no evidence that the impurity in some stocks of valsartan has caused any harm to patients. Further updates will be provided as more information becomes available.